Physician profile
Rachel Neal
NPI 1194253831
$1,134.46
in general payments reported to CMS, 2019-2025
15 companies · $280 in 2025
The $280 reported for 2025 was more than what a typical Complex Family Planning provider received nationally (typical 2025 total: $126).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $345 · 2023: $92.75 · 2024: $417 · 2025: $280.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $656 · Education: $134.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $656.21 |
| Education | $133.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medical Device Business Services, INC. | $325.00 | 2019 | |
| Millicent US INC | $177.06 | 2024-2025 | Femring, Intrarosa |
| Abbvie INC. | $132.77 | 2023-2024 | |
| Organon LLC | $84.14 | 2024-2025 | Nexplanon |
| Novo Nordisk INC | $83.22 | 2025 | Wegovy |
| Coopersurgical, INC. | $71.51 | 2023-2024 | Paragard T 380a, Paragard T 380a |
| Biogen, INC. | $52.49 | 2025 | Zurzuvae |
| Exact Sciences Corporation | $48.27 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Vertex Pharmaceuticals Incorporated | $29.10 | 2025 | |
| Sumitomo Pharma America, INC. | $28.51 | 2024 | Myfembree |
| Pfizer INC. | $25.86 | 2024 | |
| Astellas Pharma US INC | $21.29 | 2025 | Veozah |
| Ethicon US, LLC | $19.75 | 2019 | |
| Mayne Pharma Commercial LLC | $18.85 | 2024 | |
| Merck Sharp & Dohme LLC | $16.64 | 2024 | Gardasil 9, Gardasil |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Neal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.